The Impact of Partially Effective HIV Vaccine on a Population of Intravenous Drug Users in Bangkok, Thailand: A Dynamic Model

From CDC National Prevention Information Network

March 7, 2002

This article is part of The Body PRO's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.

As of 1999, HIV prevalence was 2.2 percent in Thailand and 33 percent among Thai injection drug users (IDUs) in major urban areas. Bangkok is currently the site of one of only two large-scale AIDS vaccine trials in the world. Because of the variability of HIV, the first marketed AIDS vaccine is likely only to be partially effective.

The researchers describe a mathematical model of the impact of a partially effective AIDS vaccine in a population of IDUs in Bangkok. They constructed a dynamic compartmental, or subgroup, model for Bangkok's IDUs, adapted from previous simulations of the HIV epidemic in gay males. The model consisted of 14 population subgroups, varying by high- and low-risk injection behavior, and five levels of disease status (HIV-negative; HIV-positive, asymptomatic, unidentified; HIV-positive, asymptomatic, identified; HIV-positive, symptomatic; and AIDS). Two types of risk behavior change were analyzed: positive post-counseling behavior change and a false immunity-presumptive, negative change in behavior. HIV-positive individuals were not distinguished by vaccination status because researchers assumed it had no therapeutic effect.

Transmission parameters were based on previously developed models of injection drug use. Among IDUs, injection risk behavior and viral infectivity determine how likely an individual is to become infected with HIV. Injection risk behavior characteristics include contact rate, total number of injections per year, and the probability that a needle was shared before injection.

The analysis only examined transmission through shared needle use. "Restricted" mixing between high and low-risk groups with respect to sharing needles was assumed. Input data for the model were obtained from the published literature. Population- specific data were used where possible; in the absence of Bangkok-based research, estimates were taken from US research. For base-case analysis, key assumptions were made. First, 50 percent of the eligible population is vaccinated each year. Second, the vaccine provides complete protection for 75 percent, and no protection for 25 percent, of those vaccinated. Third, the duration of protection from vaccine is ten years on average, after which individuals are not re-vaccinated. Fourth, the annual probability of any risk behavior change is 5 percent. Finally, the initial HIV prevalence is 30 percent. The analysis simulated the course of the epidemic in a population of 36,600 male IDUs during both 40 and 150 years.

Advertisement

After 40 years, HIV prevalence was 37 percent with vaccination and 50 percent without vaccination. Total population size after 40 years was 14,721 with vaccination and 10,569 without vaccination, a difference of 4,153 people. Although vaccination led to lower disease prevalence, there were higher absolute numbers of infections for 18 years starting in year 30 of the vaccine program and between 1 and 15 more AIDS cases each year for 18 years beginning in year 32. Excess infections with vaccination can be explained by the larger total population size achieved because of the reduction in HIV-related deaths.

At a vaccine efficacy of 30 percent, HIV prevalence was 44 percent after 40 years and reached an equilibrium level of 42 percent. At a vaccine efficacy of 90 percent, equilibrium prevalence was 35 percent. Vaccination remained superior to no vaccination at all levels of expected efficacy.

Post-vaccine risk behavior changes were analyzed: positive post-counseling behavior change and a false immunity-presumptive, negative change in behavior. Sensitivity analysis showed that with a 75 percent efficacy, HIV prevalence is somewhat sensitive to these behavior changes. If 100 percent of high-risk individuals switched to low risk behavior in response to vaccine-related counseling, HIV prevalence decreased to 33 percent after 40 years, an improvement of 4 percent over base-case results.

Simultaneous, unfavorable change in contact rates, number of injections and an increase of per partner infectivity had a limited effect when vaccine efficacy was 75 percent. The beneficial effects of vaccination diminished slightly as unfavorable post-vaccination behavior increased, though vaccination was always superior to no vaccination. The benefit of vaccination with a low-efficacy vaccine can be mitigated significantly by unfavorable behavior changes.

Results suggested that the effectiveness of vaccination depends on the probability of vaccination-related behavior change only if vaccine efficacy is lower than the base-case assumption of 75 percent. The findings suggest that a low-efficacy AIDS vaccine is beneficial to IDUs in Bangkok and that this beneficial effect can be enhanced or moderated by risk behavior change. If IDU behavior is modifiable, the findings have significant policy and planning implications.

TheBodyPRO.com is a service of Remedy Health Media, LLC, 750 3rd Avenue, 6th Floor, New York, NY 10017. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.